Our consultancy provides strategic direction and tactical execution for development of novel pharmaceuticals and medical devices
Medical product development is a complex, expensive, risky venture. How does one get from early findings to an approved product? How do you get to the key milestones as rapidly and efficiently as possible?
Gary Novack, Ph.D.
Gary D. Novack, Ph.D., President of PharmaLogic Development, Inc. has decades of experience in successful product development. Together with his team of senior experts, PharmaLogic can help you execute that plan.
In our 25+ years working in manifold therapeutic areas with pharmaceuticals, biologics and devices, the firm’s particular expertise is in local therapy (ophthalmology and dermatology).
Based upon decades of successful product development experience, PharmaLogic Development, Inc., can help you develop and execute a strategic plan for your product. Working in manifold therapeutic areas with pharmaceuticals, biologics and devices, our expertise is in local therapy (ophthalmology and dermatology).
Dr. Novack states “The more I work in the development of new pharmaceuticals, the more I see that early development is a complex interaction of pharmaceutics (formulation), safety assessment (local and systemic), and clinical planning. Not only do we help plan and execute what needs to be done, but what needs to be done when.”
Many of his experiences and unique perspectives in product development may be found in the over two dozen editorials he has written as a contributing editor to The Ocular Surface.
If you don’t know where you are going, any road will get you there.
– Lewis Carroll
Dr. Novack was a visiting Professor at the University of Wisconsin School of Medicine in Madison in May 2017. He presented a lecture in the Frontiers in Vision Research series about ophthalmic drug development and drug...read more
Dr. Novack attended the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Baltimore, MD. This was his approximately 33rd ARVO meeting. He presented in the Special Interest Group on the TFOS Dry Eye Workshop II. As well he had two...read more
With recent press releases by the Sponsors, there are at least five ophthalmic New Drug Applications (NDAs) under review by the U.S. FDA at this time (25 April 2017). Some of these were held up for chemistry issues in their original 2016 submissions....read more